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Abstract
Background: Oral squamous cell carcinoma (OSCC) is one of the most common forms of cancer
associated with the presence of precancerous oral leukoplakia. Given the poor prognosis
associated with oral leukoplakia, and the difficulties in distinguishing it from cancer lesions, there is
an urgent need to elucidate the molecular determinants and critical signal pathways underlying the
malignant transformation of precancerous to cancerous tissue, and thus to identify novel diagnostic
and therapeutic target.
Results: We have utilized two dimensional electrophoresis (2-DE) followed by ESI-Q-TOF-LC-
MS/MS to identify proteins differentially expressed in six pairs of oral leukoplakia tissues with
dysplasia and oral squamous cancer tissues, each pair was collected from a single patient.
Approximately 85 differentially and constantly expressed proteins (> two-fold change, P < 0.05)
were identified, including 52 up-regulated and 33 down-regulated. Gene ontological methods were
employed to identify the biological processes that were over-represented in this carcinogenic
stage. Biological networks were also constructed to reveal the potential links between those
protein candidates. Among them, three homologs of proteosome activator PA28 a, b and g were
shown to have up-regulated mRNA levels in OSCC cells relative to oral keratinocytes.
Conclusion: Varying levels of differentially expressed proteins were possibly involved in the
malignant transformation of oral leukoplakia. Their expression levels, bioprocess, and interaction
networks were analyzed using a bioinformatics approach. This study shows that the three
homologs of PA28 may play an important role in malignant transformation and is an example of a
systematic biology study, in which functional proteomics were constructed to help to elucidate
mechanistic aspects and potential involvement of proteins. Our results provide new insights into
the pathogenesis of oral cancer. These differentially expressed proteins may have utility as useful
candidate markers of OSCC.
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Backgound
Oral, head, and neck squamous cellular carcinoma is one
of the most common forms of cancer associated with the
presence of precancerous lesions. It is now believed that
OSCC follows a similar pattern in its development, and
thus is preceded by precancerous lesions, among which
oral leukoplakia (OLK) is the most common type. The
World Health Organization (WHO) first defined oral leu-
koplakia as a white plaque that could not be characterized
clinically or pathologically as any other disease in oral
mucosa. The malignant potential of oral leukoplakia was
evidenced by the progression from metaplasia without
dysplasia to low grade dysplasia, high grade dysplasia,
and ultimately to invasive carcinoma [1]. The risk of
developing malignancies is 8–10 times higher in people
who have oral leukoplakia than people who do not [2].
The risk is also increasing with the series of dysplasia
stages [3]. There is an urgent need to elucidate the molec-
ular determinants and key signal pathways underlying the
malignant transformation from precancerous to cancer-
ous tissue, and thus to identify novel diagnostic and ther-
apeutic targets.
Proteomics is an established molecular profiling technol-
ogy that may significantly accelerate human cancer
research. Recently, a lot of progress has been made in oral
cancer proteomics generating some potential applications
in this emerging field. This technology platform has been
utilized to discover highly sensitive and specific protein
markers for oral cancer diagnosis and prognosis by com-
paring the protein profiles of cancer cells [4,5], tissues [6],
plasma [7], and saliva[8,9] with appropriate controls.
However, there are fewer reports about discrimination of
protein expression profiles between tumor and precancer-
ous lesion with different stages of dysplasia.
The development of bioinformatics tools has allowed the
compilation of searchable genomic and proteomic data-
bases accessible via the Internet. Among them, the appli-
cation of Gene Ontology (GO) and the pathway analysis
was considered as a powerful tool in systematic biology
for elucidating the complexity of expression profiles in
cellular processes. The term of GO describes the role of a
given gene in a biological process, its molecular function
and cellular component. Each gene is provided with dif-
ferent levels of GO terms, ranging from high-level,
broadly descriptive terms to very low-level, highly specific
terms [10]. Thus, profiling the expression data based on
GO will provide another dimension for understanding
the key regulatory processes in oral cancer. The applica-
tion of the pathway analysis reveals the interactions
between the proteins, thus quickly generating new
insights into potential complex molecular mechanisms
underlying disease related processes [11].
In this study, we have evaluated protein expression differ-
ences to identify potential biomarkers of disease progress
from oral leukoplakia to OSCC in order to gain further
insight into potential mechanisms underlying these trans-
formations. Six pairs of protein lysates were obtained
from six patients. The tissues were analyzed by two-
dimensional gel electrophoresis, followed by ESI-Q-TOF
tandem mass spectrometry. GO analysis was applied to
identify biological processes over-represented in the car-
cinogenesis. Biological networks were also constructed to
reveal the potential links between the protein candidates.
By using this approach, new therapeutic targets or protein
markers can possibly be identified to improve patient sur-
vival.
Results
2-DE profiling of OSCC and the oral leukoplakia tissues
A total of 6 pairs of OSCC tumor tissues and the oral leu-
koplakia control tissues were obtained from 6 patients.
Figure 1 showed their representative clinical photos and
HE-staining histographs. 2-DE with immobilized pH gra-
dients was performed to study the expression patterns of
proteins extracted from both tissues, and each sample was
analyzed twice to ensure the reproducibility. Figure 2
showed representative 2-DE patterns obtained from the
paired tissues. After automatic spot detection, background
subtraction, and volume normalization, 859 ± 68 protein
spots in OSCC tissue, and 844 ± 56 protein spots in con-
trol tissues were detected. Of these spots, 730 (85%) in
OSCC tissues and 708 (84%) in control tissues were
reproducibly detected in all of the twelve runs, and only
the reproducibly detected spots were subjected to statisti-
cal analysis(p < 0.05). As a result, 85 protein spots showed
more than two fold changes in at least 4 of the twelve
repeats (marked in figure 2) while 68 proteins (80%)
repeated in more than 8 of 12 pairs.11 proteins were
selected as examples (boxed in figure 2) showing the con-
sistent expression changes in enlarged form (see addi-
tional file 1).
Identification of putative OSCC biomarkers
As shown in Table 1, a total of 85 differentially expressed
proteins, including 52 up-regulated and 33 down-regu-
lated proteins, were identified. Proteasome activator com-
plex PA28 a and b were chosen for further validation. They
both exhibited a high expression level in cancer tissues
(4–6 fold increase) when compared with the precancer-
ous OLK tissues. The mass spectra for both were shown in
Figure 3.
Finding functional enrichment in transformation from oral 
leukoplakia to OSCC through gene ontology
Ontological methods were employed to structure the bio-
logical processes that were over-represented in the carci-
nogenic stage from oral leukoplakia to infiltrative oralBMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
Page 3 of 17
(page number not for citation purposes)
cancer. A web-based tool (GOTree) was employed in
which the biological process of the proteins encoded by
the genes is scored. Those with a level higher than 4 were
highlighted. The observed versus the expected number of
genes in the GO categories using a Homo sapiens reference
data set was analyzed. 18 novel proteins, each marked
with an asterisk in Table 1, were demonstrated to be
expressed in head and neck by the analysis of tissue
expression profile using GOTree, and their bar chart is
shown in Figure 4. X-axis represented the different tissue.
The Y-axis means the proteins has been reported in corre-
sponding tissue. Figure 5 shows the tree-like structure
with their respective molecular functions, cellular compo-
nents and biological processes. Taken the biological proc-
esses as an example, it involved six processes, the
processes responsive to stimulus (including heat shock 70
kDa, 60 kDa and 27 kDa proteins, tubulin, heat shock 70
kDa protein 8, annexin A5, proliferating cell nuclear anti-
gen, S100A7,8,9, annexin A1 and A8, and interleukin 4);
physiological response(including serpin peptidase inhibi-
tor, Rho GDP dissociation inhibitor beta, fibrinogen,
PA28 a and b); negative regulation of biological process
(including capping protein muscle, annexin A4, SET trans-
location, glutathione S-transferase, S100A11, annexin A1,
non-metastatic cells 2 protein, and prohibitin); locomo-
tion proteins (including annexin A1, SERPINB5, Rho
GDP dissociation inhibitor (GDI) alpha, tropomyosin 1,
and heat shock 27 kDa protein 1); cell death process
(including heat shock 27 and 70 kDa protein, annexin A4
annexin A5, galectin 7, and prohibitin); and coagulation
(including annexin A4, A5, A8, and fibrinogen).
Link of the Proteins to Biological Pathways
To establish an overview of the interactions among differ-
entially regulated proteins, and to prioritize proteins and
pathways for further evaluation, we used the Pathway Stu-
dio software to explore the associations between differen-
tially regulated proteins, essentially based on the available
knowledge about eukaryotic molecular interactions docu-
mented in the ResNet database. Notably, central nodes of
proteins of the biological network, generated by the Path-
way Architect assembly of GO designations for the most
prominently over-represented genes, were shared in oral
leukoplakia tissues and tumor tissues including S100 fam-
ily (A7, 8, 9, 10, and 11), HSP family (HSPB1 and
HSPA8), ANX family (A1, 3, 4, and 5), tumor metastasis
suppressor NME2 and Rho GDP dissociation inhibitor
alpha and beta (ARHGDIA and B), pyruvate kinase
(PKM2), transgelin (TAGLN), glutathione S-transferase
(GSTP1), SERPINA1, PCNA, and so on (Figure 6A). Those
proteins and their interactive pathways merit further study
for their roles in oral carcinogenesis.
Representative clinical and histological pictures Figure 1
Representative clinical and histological pictures. Representative clinical (A) and histological pictures (B, C, D) showing a 
pair of OSCC and oral leukoplakia tissues with dysplasia obtained from the same patient.BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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Biological Pathways related to PA28
Pathway analysis was also used to reveal the protein inter-
actions and potential pathways of PA28. The result
showed that some proteins interacted with PA28 either
directly or indirectly, which was not identified by the pro-
teomics approach due to their low abundance (Figures
6B). It was generally accepted that PA28ab contributes to
Class I presentation in immune tissues. Our results also
reinforced the connection between PA28ab and cellular
immunity as the proteins involved in the MHC-I antigen
presenting pathway like PA28, proteosome, HSP70 and
HSP90 have been detected to be up-regulated (Table 1,
Figures 6C).
Overexpression of PA28 in OSCC Cancer Cells and Cancer 
Tissues
Evaluation of PA28 expression in seven OSCC cell lines
relative to the human immortalized oral keratinocytes
(HOK16E6E7) and of PA28 expression in OSCC tumor
tissues versus oral leukoplakia tissues was performed by
real time RT-PCR and Western blotting. Consistent with
observations from 2-DE, expression of PA28 was mark-
edly increased at both the mRNA and protein levels in
OSCC cells and tumor tissues compared with normal
keratinocytes and oral leukoplakia tissues (Figure 7).
Discussion
Only a few studies were done on proteomic analysis of the
malignant transformation mechanism from precancerous
lesion with different stage of dysplasia into invasive can-
cer. We have performed a comparative proteomic analysis
to profile differentially expressed proteins in the transfor-
mation process. Using GO analysis, we further analyzed
the biological process and pathway network of these pro-
teins, which can generate a new insight into systemic biol-
ogy in carcinogenesis.
Oral squamous carcinoma, like esophageal adenocarci-
noma, has been associated with the presence of precancer-
ous lesion with different stage of dysplasia, thus providing
a good model to elucidate every stage of carcinogenesis in
more detail. In our study, each pair of precancerous and
cancer tissues was from the same patient, which provides
an opportunity to eliminate or at least reduce heterogene-
ity. Using the proteomic approach, we have identified 85
differently expressed gene products and found some pro-
Representative two-dimensional maps marked altered proteins Figure 2
Representative two-dimensional maps marked altered proteins. Representative two-dimensional maps of a pair of 
OSCC cancer tissue and precancerous oral leukoplakia tissue from the same patient. The proteins were separated on a pH 3–
10 nonlinear IPG strip, followed by a 12% SDS-polyacrylamide gel, as stated under Methods. The gel was Coomassie-blue 
stained and the spots were analyzed by ESI-Q-TOF-LC-MS/MS. Arrows indicate identified protein spots significantly and con-
sistently altered between carcinoma tissue and control tissue. 11 boxed proteins were selected as examples showing the con-
sistent expression changes in enlarged form in additional file 1.BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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Table 1: Summary of protein alterations
Spot numbera Swissprot No.b Protein name Mrc PId Scoree Peptidesf Mean foldg Repeath
1 *Q5T2P8 Annexin A8-like protein 1 37086 5.45 221 13 -3.09 ± 0.24 8
2 P13928 Annexin A8 36842 5.56 269 11 -2.98 ± 0.26 8
3 Q01105 Protein SET 33469 4.23 107 5 5.89 ± 0.52 6
5 Q99497 Protein DJ-1 20,050 6.33 187 5 3.22 ± 0.43 8
4 P52907 F-actin-capping protein subunit alpha-1 32902 5.45 118 6 2.23 ± 0.31
6 Q13765 Nascent polypeptide-associated complex subunit 
alpha
23370 4.52 451 10 4.37 ± 0.51 8
7 *P24534 Elongation factor 1-beta 24748 4.5 45 1 2.42 ± 0.3 8
8 *P02533 Keratin, type I cytoskeletal 14 51589 5.09 432 17 4.32 ± 0.56 8
9 P09493 Tropomyosin alpha-1 chain 32746 4.69 162 15 6.27 ± 0.38 8
10 P08107 Heat shock 70 kDa protein 1 70009 5.48 234 8 2.33 ± 0.28 8
11 *P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 33650 4.95 140 9 2.95 ± 0.35 6
12 P10809 60 kDa heat shock protein, mitochondrial 
precursor
61016 5.7 103 7 -4.32 ± 0.58 10
13 P12004 Proliferating cell nuclear antigen 28750 4.57 113 4 7.95 ± 0.38 12
14 P40261 Nicotinamide N-methyltransferase 30011 5.56 59 10 -4.06 ± 0.58 8
15 Q9UL46 PA28 b 27515 5.44 759 28 5.88 ± 0.68 12
16 P52566 Rho GDP-dissociation inhibitor 2 23031 5.1 248 11 3.14 ± 0.28 12
17 * P02679 Fibrinogen gamma chain precursor 51479 5.37 326 18 -3.05 ± 0.42 8
18 P52565 Rho GDP-dissociation inhibitor 1 23193 5.02 211 9 3.44 ± 0.32 12
19 * P05112 Interleukin-4 precursor 17481 9.17 81 1 4.12 ± 0.62 4
20 *P68363 Tubulin alpha-1B chain 50120 4.94 325 16 3.86 ± 0.31 10
21 P05388 60S acidic ribosomal protein P0 34252 5.71 68 6 5.24 ± 0.71 6
22 Q07021 Complement component 1 Q 31742 4.74 309 6 2.12 ± 0.49 8
23 *P02675 Fibrinogen beta chain precursor 56577 8.54 236 18 13.65 ± 1.44 8BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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24 *P01009 Alpha-1-antitrypsin precursor 46707 5.37 99 2 4.22 ± 0.65 4
25 P09936 Ubiquitin carboxyl-terminal hydrolase isozyme L1 25151 5.33 326 22 11.5 ± 0.84 4
26 P09211 Glutathione S-transferase P 23341 5.43 468 16 5.44 ± 0.24 12
27 P07437 Tubulin beta chain 50095 4.78 197 12 5.67 ± 1.02 10
28 P14618 Pyruvate kinase isozymes M1/M2 58470 7.96 285 18 5.22 ± 0.29 12
29 Q06323 PA28 a 28705 5.78 147 9 4.44 ± 0.25 12
30 P04792 heat shock 27 kDa protein 1 22768 5.98 565 42 5.56 ± 0.37 10
32 P30048 peroxiredoxin 3 27675 7.67 367 28 3.04 ± 0.4 10
31 *P11142 Heat shock cognate 71 kDa protein 70854 5.37 134 7 5.26 ± 0.79 8
33 Q13162 Peroxiredoxin-4 30521 5.86 95 8 4.74 ± 0.22 12
34 P36952 Serpin B5 precursor 42111 5.72 324 19 5.26 ± 0.47 12
35 Q15019 Septin-2 41461 6.15 191 6 3.88 ± 0.65 8
36 Q01469 Fatty acid-binding protein, epidermal 15155 6.6 41 3 6.24 ± 0.25 12
37 *P19013 Keratin, type II cytoskeletal 4 57649 6.25 1023 28 3.12 ± 0.70 4
38 P60709 Actin, cytoplasmic 1 42052 5.29 806 28 5.88 ± 1.02 6
39 Q969H8 Uncharacterized protein C19orf10 18897 6.2 167 11 3.23 ± 0.56 8
40 P47929 Galectin-7 15066 7.03 730 22 6.44 ± 0.26 12
41 * P06733 Alpha-enolase 47139 7.01 1000 27 4.33 ± 0.49 8
42 P60903 Protein S100-A10 11196 6.82 149 18 5.45 ± 0.62 6
43 P62937 Peptidyl-prolyl cis-trans isomerase A 18229 7.68 2056 75 5.68 ± 0.85 6
44 P23528 Cofilin-1 18491 8.22 1677 35 3.11 ± 0.42 8
45 *P22392 Nucleoside diphosphate kinase B 17287 8.52 235 20 4.44 ± 0.23 12
46 Q01995 Transgelin 22596 8.87 238 16 3.28 ± 0.19 12
47 P01834 Ig kappa chain C region 11602 5.58 228 24 3.44 ± 0.65 10
Table 1: Summary of protein alterations (Continued)BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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48 P31949 Protein S100-A11 10173 6.56 185 8 5.56 ± 0.75 8
49 P62736 Actin, aortic smooth muscle 41982 5.23 119 6 3.67 ± 0.55 8
50 Q64133 Amine oxidase [flavin-containing] A 60157 7.94 111 1 7.56 ± 0.8 6
51 P47755 F-actin-capping protein subunit alpha-2 32929 5.57 119 11 3.24 ± 0.45 8
52 Q96A32 Myosin regulatory light chain 2, skeletal muscle 
isoform
19116 4.91 517 33 5.73 ± 0.35 12
53 *P02743 Serum amyloid P-component 25485 6.1 140 5 -2.34 ± 0.45 6
54 P02511 Alpha-crystallin B chain 20146 6.76 874 34 -9.5 ± 1.05 10
55 P61088 Ubiquitin-conjugating enzyme E2 N 17184 6.1 3 86 -3.23 ± 0.45 10
56 P08758 Annexin A5 35914 4.94 496 10 -5.74 ± 0.28 12
57 P62942 FK506-binding protein 1A 11943 7.88 51 2 -2.56 ± 0.45 12
58 P68871 Hemoglobin subunit beta 16102 6.75 996 45 -2.02 ± 0.52 8
59 Q14152 Eukaryotic translation initiation factor 3 subunit I 36479 5.38 190 15 -2.96 ± 0.47 10
60 P06702 Protein S100-A9 13234 5.71 548 23 -6.42 ± 0.58 12
61 P04083 Annexin A1 38690 6.57 2528 60 -5.03 ± 0.28 12
62 P55083 Microfibril-associated glycoprotein 4 28972 5.38 95 1 -3.69 ± 0.55 8
63 P40925 Malate dehydrogenase cytoplasmic 36,403 6.91 4 86 -2.87 ± 0.62 8
64 P27482 Calmodulin-like protein 3 16937 4.3 1562 55 -4.22 ± 0.35 10
65 * P61158 Actin-related protein 3 47341 5.61 93 9 -2.14 ± 0.45 8
66 *P02768 Serum albumin precursor 71317 5.92 856 52 -7.67 ± 0.85 10
67 P05109 Protein S100-A8 10828 6.51 136 13 -3.34 ± 0.55 12
68 *P05976 Myosin light chain 1, skeletal muscle isoform 21132 4.97 881 49 -13.5 ± 0.85 12
69 P30086 Phosphatidylethanolamine-binding protein 1 21044 7.01 210 5 -3.78 ± 0.65 6
70 P11177 Pyruvate dehydrogenase E1 component subunit 
beta,
39208 6.2 64 5 -5.35 ± 0.25 12
71 P31151 Protein S100-A7 11564 6.28 131 7 -6.23 ± 0.44 12
Table 1: Summary of protein alterations (Continued)BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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72 Q96FQ6 Protein S100-A16 11794 6.28 68 4 -7.14 ± 0.86 8
73 P49773 Histidine triad nucleotide-binding protein 1 13793 6.43 40 3 -3.23 ± 0.52 8
74 P69905 Hemoglobin subunit alpha 15305 8.72 769 43 -7.68 ± 1.04 8
75 P04080 Cystatin-B 11133 6.96 378 28 -3.89 ± 0.18 12
76 P07195 L-lactate dehydrogenase B chain 36615 5.71 246 12 -2.69 ± 0.55 6
77 P02144 Myoglobin 17173 7.14 2284 53 -19.22 ± 1.38 12
78 O00299 Chloride intracellular channel protein 26906 5.09 405 16 -2.23 ± 0.48 6
79 P07737 Profilin-1 15216 8.44 1252 53 -5.69 ± 0.35 12
80 O95994 Anterior gradient protein 2 homolog 19967 9.03 292 10 -2.87 ± 0.52 8
81 *P62988 Ubiquitin 18560 6.56 112 5 -5.22 ± 0.43 6
82 P45378 Troponin T, fast skeletal muscle 31805 5.71 233 10 -2.99 ± 0.45 8
83 P12429 Annexin A3 36353 5.63 169 10 -4.41 ± 0.28 12
84 P09525 Annexin A4 35860 5.84 694 20 -2.88 ± 0.56 8
85 P35232 Prohibitin 29843 5.57 214 14 -3.24 ± 0.45 8
a The spot number correspond to those on 2-DE images shown in Fig. 2
b Swiss-Prot accession number.
c Theoretical molecular mass (kDa) and pI from the ExPASy database.
d Theoretical pI from the ExPASy database.e The number of unique peptides identified by MS/MS sequencing.
f Probability-based MOWSE (molecular weight search) scores. g Expression change level in OSCC tumor tissue compared with control (+, increase 
in tumor;-, decrease in tumor). Data were represented as mean ± SD
h frequency of the up-regulation (or down-regulation) of the 85 proteins identified in the six sample pairs.
* new proteins obtained by analysis of expression pattern through web-based tool (GOTree)
Table 1: Summary of protein alterations (Continued)BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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teins are related to apoptosis, response to stimulus, meta-
bolic regulation and etc. We can thus conclude that these
proteins may play an important role in malignant trans-
formation process. Our most significant finding was that
several proteins in the same protein families and
homologs were identified in this transformation process,
such as peroxiredoxins (Peroxiredoxin-3 and 4), Annexin
family (A1, A 3, A 4, A 5, A 8), Rho GDP-dissociation
inhibitor 1 and 2, Heat shock protein family (70 kDa pro-
tein 1, 71 kDa protein, and Heat shock protein beta-1),
PA28 homolog (PA28 a and b), Protein S100 family (A7,
A8, A9, A10, A11, and A16). Among which, the annexins
and S100 are two super-families of closely related calcium
and membrane-binding proteins and their relationship
with carcinogenesis has been widely studied. They have a
diverse range of cellular functions including vesicle traf-
ficking, cell division, apoptosis, calcium signaling and
growth regulation.
Many studies have revealed the annexins to be among the
genes whose expression is differentially altered in neopla-
sia. Some annexins showed increased expression in spe-
cific types of tumors, while others displayed loss of
expression. In our report, the expression level of annexin
A1, 3, 4, 5, 8 were all decreased while annexin A8 showed
increased expression. Annexin A1 has been extensively
studied  in vitro and  in vivo. The loss of expression of
annexin A1 in our study confirmed previous findings in
head and neck squamous carcinomas[12]. Expression of
annexin A3 has only been studied in a limited number of
tumor types with only one report regarding its expression
in head and neck cancer [13]. For annexin A4, a few stud-
ies reported its increased expression in clear cell renal can-
cer and colorectal cancer by using a combination of
proteomics tools [14,15]. The change of Annexin A5 was
also observed in our study, which has been considered as
one of the signals on the surface of the apoptotic cells and
has been used as a probe for apoptosis [16]. Annexin A8
has been shown to be consistently over-expressed in acute
promyelocytic leukaemia, breast cancers, pancreatic can-
cer by a combination of gene expression microarrays and
immunohistochemistry. The expression of annexin A4, 5,
Results of PA28 b and a as the representative protein identified using ESI-Q-TOF-MS/MS Figure 3
Results of PA28 b and a as the representative protein identified using ESI-Q-TOF-MS/MS. A a b, output of the 
database searching by the MASCOT program using MS/MS data used in the identification of PA28 b. The matched peptides 
were shown in bold red. A c d, MS/MS spectrum of parent ions with m/z values of 1533.7311(arrow marked). B a b, output of 
the database searching by the MASCOT program using MS/MS data used in the identification of PA28 a. B c d, MS/MS spectrum 
of parent ions with m/z values of 1518.7314(arrow marked).BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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and 8 in head and neck cancer has been reported in this
study for the first time, which was consistent with the
results obtained in other studies concerning their expres-
sion in other cancers [17,18].
The S100 proteins are a multi-gene calcium-binding fam-
ily of proteins comprising 20 known human members.
There has been growing interest in the S100 protein fam-
ily and their relationship with different cancers. While the
precise role of S100 proteins in the development and pro-
motion of cancer remains unclear, it is evident that the
S100 proteins have a variety of intracellular and extracel-
lular roles, and that disruption of any one of these func-
tions may contribute to carcinogenesis. There is evidence
that these proteins play a major role in tumor metastasis
by interacting with a number of different proteins, includ-
ing matrix metalloproteinase, cytoskeletal proteins, p53,
Jab1, Cox-2 and BRCA1. In this study, we have identified
a series of members including S100A7, 8, 9, 10, 11, and
16 with differential expression in OSCC tissues. S100A7
(psoriasin) was a member first characterized as being
highly expressed in psoriatic keratinocytes [19]. There is
accumulating evidence that S100A7 is up-regulated in
bladder cancer skin tumors and some invasive carcino-
mas. Its expression is associated with a poorer prognosis
and reduced survival [20-22]. On the contrary, other
reports in OSCC showed its expression was associated
with a better prognosis based on the finding that S100A7
is highly expressed in pre-invasive, well-differentiated and
early staged OSCC, but little or no expression was found
in poorly differentiated, later-staged invasive tumors [23].
Other reports showed that S100A7 inhibits both OSCC
cell proliferation in vitro and tumor growth/invasion in
vivo [24]. These results were echoed by our study, in
which S100A7 was identified to be down-regulated in the
transformation process form precancerous dysplasia to
invasive cancer. Therefore, unlike in other tumors, our
data suggests S100A7 to be a tumor suppressor in OSCC.
The detailed function should be further elucidated.
S100A8 and S100A9 which form a heterodimer complex
90 are up-regulated in many cancers and have been impli-
cated in the metastatic process including gastric cancer,
prostate cancer, colorectal cancer, and breast cancer [25-
27]. In OSCC, one study reported there was more than a
10-fold over-expression of S100 A8 in HPV18+ OSCC
[28]. For S100A11, its function has been somewhat con-
troversial. In bladder carcinoma and renal carcinoma, its
expression is related to tumor suppression, and decreased
expression of S100A11 has been associated with an
increase in histopathological grade, poorer prognosis and
Expression Profiling Diagram Figure 4
Expression Profiling Diagram. The diagram was constructed with the use of the Ingenuity Pathway Analysis software as 
described in Materials and Methods and in Results. 18 novel proteins were shown to be firstly expressed in head and neck.BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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decreased survival [29]. However, in prostate cancer and
breast cancer it is thought to be a tumor promoter. Its
increased expression in prostate cancers has been shown
to be associated with advanced pathological stage [30].
There is only one report about the gene expression of
S100A11 related to its diverse functions [31]. S100A16
protein, a new and unique member of the EF-hand Ca
(2+)-binding proteinswas found to accumulate within
nucleoli and be translocated to the cytoplasm in response
to Ca (2+) stimulation [32]. Here we report for the first
time the expression of S100A16 protein in carcinogenesis
from precancerous dysplasia to OSCC. It is possible that
each S100 protein may play multiple roles in tumourigen-
esis and metastasis. This highlights the need for an
improved understanding of the S100 family, before the
design of S100 protein-targeted therapies can be achieved.
Proteasomes are large complexes that carry out crucial
roles in many cellular pathways by degrading proteins in
the cytosol and nucleus of eukaryotic cells [33]. Proteas-
omes are activated by protein complexes that bind to the
end rings of subunits. PA28 (also known as 11S or REG)
has been shown to bind specifically to and activate 20S
proteasomes against model peptide substrates [34]. The
biological roles of PA28 are less well understood. There
are three PA28 homologs, called a, b and g. Although
PA28a and b subunits are expressed in many organs, they
are particularly abundant in immune tissues and are virtu-
ally absent from the brain. By the late 1990s, PA28ab was
found to contribute to Class I presentation, based on the
high levels of PA28ab in immune tissues, the IFNg induc-
tion of PA28ab and many components of the class I path-
way, and the direct production of some Class I epitopes by
PA28ab-proteasome complexes[35,36]. Our results also
reinforce the connection between PA28ab and cellular
immunity by showing that the key proteins in the MHC I
antigen presenting pathway like PA28, proteosome,
HSP70 and HSP90 have been detected up-regulated in
OSCC tissues. An earlier study showed that PA28g expres-
sion correlated with cell proliferation. Recently, some
researchers have gained more insight into the role of
PA28g in apoptosis [37]. These findings were paralleled
by studies suggesting that PA28g functions in cell cycle
progression and has an immune role [38]. Two-hybrid
screens have identified several proteins that interact with
PA28g as well. Interestingly, all these findings suggest that
PA28g is an anti-apoptotic factor. Less is known about
how PA28g may suppress apoptosis in oral carcinesogen-
esis. In our validation study, Three homologs were all
included. The results have confirmed the up-regulation of
PA28 in carcinogenesis by comparison between several
OSCC cell lines and oral keratinocytes. In our further
studies, we would valuate the PA28 ab complex and PA28
g immunostaining pattern in different stage of tissue sam-
ples from normal, precancerous to infiltrative OSCC.
Moreover, the relationships of immunostaning with sur-
vival rate and recurrence will be analyzed.
Directed acyclic graph (DAG) view of the enriched GO categories in the transformation process from precancerous oral leu- koplakia to OSCC Figure 5
Directed acyclic graph (DAG) view of the enriched GO categories in the transformation process from precan-
cerous oral leukoplakia to OSCC. The enriched GO categories were brought together and visualized as a DAG. Catego-
ries in red were enriched, while those in black were non-enriched parents http://bioinfo.vanderbilt.edu/gotm/. A) biological 
process, B) physiological process C) response to stimulus D) molecular function E) cellular component.BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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Figure 6 (see legend on next page)BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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Organization of dysregulated protein genes into common pathways in the transformation process from precancerous oral leu- koplakia to OSCC by Pathway Studio Figure 6 (see previous page)
Organization of dysregulated protein genes into common pathways in the transformation process from pre-
cancerous oral leukoplakia to OSCC by Pathway Studio. Proteins with their SWISS-PROT number were loaded into 
Pathway Studio software http://www.ariadnegenomics.com/, and analyzed using the Pathway Studio program with the ResNet 
2.5 database. (A) 85 protein genes with a high confidence index of interactions were included in the pathway layout graph. (B) 
The indirect interaction of eight proteins with PA28 a and b (gene name: PSME1 and 2) as reported in the cancer-related liter-
ature. (C) The key proteins in MHC antigen presenting pathway, among which PA28, proteosome, HSP70 and HSP90 have 
been detected up-regulated in our study. Each node represents either a protein entity or a control mechanism of the interac-
tion. Connecting lines between the protein symbols indicate interactions; different types of interactions are denoted by sym-
bols on the lines. Green square indicates regulation; purple square, binding; blue square, expression; orange circle, protein 
modification; red diamond, metabolism; green circle, promoter binding; yellow triangle, transport; "+" in gray circle, positive 
effect; and "-" in gray circle, negative effect.
Validation of PA28 in OSCC tissues and cells relative to control oral leukoplakia tissue and normal keratinocytes Figure 7
Validation of PA28 in OSCC tissues and cells relative to control oral leukoplakia tissue and normal keratinoc-
ytes. (A, B, C) The mRNA expression evaluated by real-time PCR in seven OSCC cell lines when compared to the oral kerat-
inocytes. The mRNA level of the three PA28 homologs, a, b and g were shown in A, B, and C, respectively. Except PA28 a in 
KB and Tca8113 cell lines, the mRNA expression in OSCC cells were reproducibly increased. (D) Crops of images of quantita-
tive measurement of PA 28 g protein in 3 pairs of OSCC tissues (Ca) and oral leukoplakia tissues (control) by Western blotting 
analysis using PA 28 g-specific antibody. (E) The mRNA expression evaluated by real-time PCR in 4 pairs of OSCC tissues and 
oral leukoplakia tissues.BMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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Conclusion
In summary, we have applied proteomic technologies to
analyze the malignant transformation from precancerous
oral leukoplakia to oral cancer from 6 patients, and we
have identified 85 different proteins with altered expres-
sion levels in OSCC in the transformation, of which 53
were up-regulated. Previous characterizations regarding
their functions and possible interactions with other pro-
teins and in particular the pathways involved were also
evaluated. As a key factor in tumor metastasis, PA was cho-
sen for transformation at first. The proteosome activator
PA28 was studied for their expression and interactive net-
works correlated with oral malignancy. We have being
started the further research on other potential biomakers
like peroxiredoxins, annexin family and S100 family. This
is an example of a systems biology study, in which func-
tional proteomics was constructed to help to elucidate
mechanical aspects and potential involvement of proteins
of interest in biological pathways.
Methods
Cell Culture
Seven oral squamous cell carcinoma cell lines (SSC4,
SCC9, SCC15, SCC25, Cal 27, KB, Tca8113) were main-
tained in Dulbecco's modified Eagle's medium (Invitro-
gen) containing 10% fetal calf serum (Invitrogen), 100
units/liter penicillin, and 10 mg/liter streptomycin.
HOK16E6E7 cells, a human immortalized oral keratinoc-
yte cell line, was cultured in keratinocyte growth medium
containing 0.15 Mm calcium and supplemented with epi-
dermal growth factor (Invitrogen). All cell lines were
maintained at 37°C in an atmosphere containing 5%
CO2.
Tissue collection and sample preparation
Six pairs of tumors and oral leukoplakia tissues with dys-
plasia were obtained from six patients in West China Sto-
matological Hospital, Sichuan University. The specimens
were examined histologically by hematoxylin and eosin
(HE) staining, and the clinicopathologic stage was deter-
mined according to the TNM classification system of the
International Union against Cancer [39]. Patients receiv-
ing previous chemotherapy or radiation treatment were
excluded. All the tissue specimens were snap-frozen in liq-
uid nitrogen for proteomic analysis. Hematoxylin-stained
5 μm frozen sections were reviewed by a Board-Certified
pathologist (Y. Chen) for tumor cellularity (oral squa-
mous carcinoma) or oral leukoplakia mucosa (moderate-
high grade dysplasia). Informed consent was obtained
from all patients or their relatives for the experimental use
of their tissues. Medical records were reviewed and data
were coded to protect patient confidentiality. The project
was approved by the Scientific and Ethics Committee of
Sichuan University.
Two-Dimensional Electrophoresis
Two-dimensional gel electrophoresis was performed
essentially as previously described [40]. The protein con-
centration of the supernatants was determined using a
Bio-Rad protein kit. All the paired samples were quantita-
tively analyzed in group. Samples of 1 mg protein were
applied on immobilized pH 3–10 nonlinear gradient
strips in sample cups at their basic and acidic ends. Focus-
ing started at 200 V and the voltage was gradually
increased to 8000 at 4 V/min and kept constant for a fur-
ther 3 h (approximately 150 000 Vh totally). The second
dimensional separation was performed in 12% SDS-poly-
acrylamide gels. The gels (180 × 200 × 1.5 mm3) were run
at 40 mA/gel. After protein fixation in 50% methanol con-
taining 5% phosphoric acid for 2 h, the gels were stained
with Coomassie Brilliant Blue R-250 (Merck, Germany)
for 12 h and the protein spots were visualized. Each exper-
iment was performed twice to ensure the accuracy of anal-
yses. The images were scanned using a Bio-Rad high
quality white light GS-800 scanner (400–750 nm). The
differentially expressed proteins were identified using the
PD-Quest 2DE analysis software (Bio-Rad, USA). The
quantity of each spot in a gel was normalized as a percent-
age of the total quantity of all spots in that gel and evalu-
ated in terms of O.D. The student's t-test was applied to
compare the spot relative volume between two groups.
Significant spots that showed changed consistently and at
least 2.0-fold difference (p < 0.05) were selected for tan-
dem mass spectrometry (MS/MS) analysis.
Protein identification by nano-HPLC-ESI-Q-TOF-MS/MS
The protein spots were excised manually and digested
using sequence grade trypsin (V511A, Promega). The pro-
tein samples were reduced, alkylated, and then digested
with trypsin using standard protocols as previously
described. The digests were analyzed using a nano-HPLC
system coupled to Q-TOF Primer mass spectrometer (Q-
TOF, Micromass, Micromass, Manchester, UK) equipped
with an electrospray ionization source. Spectra were accu-
mulated until a satisfactory signal/noise ratio had been
obtained. Only double, or more than double, charge
peaks, in the mass range from 400 to 1600 m/z, were con-
sidered for MS/MS. Ions exhibiting a detection intensity
exceeding 10 counts/second were selected for production
of ion spectra by Collision Induced Dissociation (CID).
Trypsin autolysis products and keratin-derived precursor
ions were automatically excluded. Three MS/MS ions were
selected for each survey scan. All data used to extract peak
information, which was used to create the MS/MS peak
list, were generated from one combined spectrum. The
tandem mass spectrometry (MS/MS) data, "pkl list (pkl) "
files acquired by the software of ProteinLynx 2.2.5
(Waters), included the mass values, the intensity and the
charge of the precursor ions (parent ions with +2 or +3
charge in this study). The pkl files were analyzed usingBMC Genomics 2009, 10:383 http://www.biomedcentral.com/1471-2164/10/383
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MASCOT search engine http://www.matrixscience.com
against SWISS-PROT protein database. Proteins were
identified on the basis of two or more peptides whose ion
scores both exceeded the threshold, P < 0.05, which indi-
cated the 95% confidence level for these matched pep-
tides [41].
Functional genome (Gene) ontology analysis
To translate sets of differentially regulated genes into func-
tional profiles, we applied GOTree Machine http://bio
info.vanderbilt.edu/gotm/ for data analysis. GOTree
Machine generates a GOTree, a tree-like structure to navi-
gate the Gene Ontology-directed acyclic graph for input
protein sets, and to provide navigational data and visual-
ization. The software categorizes gene products based on
the location of the protein within cellular components
and suggests possible biochemical, biological, and molec-
ular functions. Statistical analysis was performed to iden-
tify the most important GO categories for the input
protein sets and to suggest their potential biological
importance in each of the categories. The tissue expression
pattern diagram was constructed with the software too.
Biological association network
Changes in gene/protein expression are not isolated
events. Therefore, we hypothesize that differentially regu-
lated genes/proteins that have interacted with others may
be more likely to play crucial roles in oncogenesis. To
identify those key factors, we explored the biological asso-
ciations among the differentially expressed proteins using
String http://string.embl.de/. Differentially expressed pro-
teins each identified with a SWISS-PROT number were
uploaded into String. The proteins were integrated into
biological association networks based on protein interac-
tions documented in a curated database
Real-Time Quantitative PCR
Real-time PCR was performed on a LightCycler (Roche
Diagnostics) platform as previously described [42]. The
following forward and reverse primers were selected by
using PRIMER EXPRESS software and were synthesized by
TaKaRa Co. Ltd. PA28 a F: 5'-GCC AAC TTG AGC AAT
CTG A-3'; PA28 a R:5'-ACA GGG AGG ACC TTT GTC-3';
PA28 a TM: 5'-FAM-AGAAAGAGGAGCGGAA-
GAAACAGC-ECLIPSE-3'; PA28 b F: 5'-TAG CGA CTG
AAG CAG CAT G-3'; PA28 b: 5'-GGA AGT CAA GTC AGC
CAC AT-3'; PA28 b TM: 5'-FAM-ATT CCT CTA CAG ATT
CTT GCC ACA GA-ECLIPSE-3'; PA28 g F: 5'-AGA AGA CTT
GGT GGC AAA T-3'; PA28 g R: 5'-TCC AGT CCA TCA TGG
CTA T-3'; PA28 g TM: 5'-FAM-CAT GAA TCT CCC AGT
CCC TGA CCC-ECLIPSE-3'. A SYBR green PCR kit
(Applied Biosystems) was used by following the manufac-
turer's instructions, and the analyses were performed in
duplicate or triplicate. Target mRNA values were normal-
ized by using β-actin mRNA as an internal control.
Western Blotting
Protein extracts were prepared using a lysis buffer contain-
ing protease inhibitor mixture 8340. For Western blotting
analysis, 20 ug of protein were separated by 12% SDS-
PAGE, then transferred to a PVDF membrane (Millipore),
and probed with monoclonal mouse anti-PA28 g anti-
body (1:1000; Cell signaling Technology). The blots were
labeled with horseradish peroxidase-conjugated second-
ary antibodies (1:10,000) and visualized with an ECL
detection system (Pierce).
Statistical Analysis
All samples were processed twice by 2-D gels and real-
time PCR. The results of the individual analyses correlated
well with each other without unexpected deviations. The
comparison was done by unpaired Student's t test. Signif-
icance was set a p < 0.05. Computations were performed
using the SPSS version 11.5 software package.
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